Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

Amarin reported additional data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) showing that the drug led to a 30% reduction in total CV events vs. placebo (RR=0.70, 95% CI: 0.62, 0.78, p<0.0001).

Amarin Corp. plc (NASDAQ:AMRN) plans to submit an sNDA to FDA by the end of the month seeking to expand Vascepa's label to include the cardioprotective effect of the drug observed in REDUCE-IT...